NIOX Group (LON:NIOX) Insider Jonathan Emms Sells 71,230 Shares of Stock

NIOX Group Plc (LON:NIOX) insider Jonathan Emms sold 71,230 shares of the stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of GBX 80, for a total transaction of £56,984.

Jonathan Emms also recently made the following trade(s):

• On Tuesday, October 27th, Jonathan Emms sold 64,166 shares of NIOX Group stock. The stock was sold at an average price of GBX 80, for a total transaction of £51,332.80.

NIOX Group Trading Up 0.3%

Shares of NIOX stock traded up GBX 0.20 during trading hours on Wednesday, reaching GBX 64.60. 281,066 shares of the stock were exchanged, compared to its average volume of 902,221. The firm has a market capitalization of £271.88 million, a price-to-earnings ratio of 39.63 and a beta of 0.92. NIOX Group Plc has a 12-month low of GBX 53.84 and a 12-month high of GBX 80. The company’s 50-day moving average price is GBX 67.34 and its 200-day moving average price is GBX 63.13. The company has a current ratio of 4.60, a quick ratio of 1.94 and a debt-to-equity ratio of 1.06.

NIOX Group (LON:NIOX) last announced its earnings results on Wednesday, September 30th. The company reported GBX 1.41 earnings per share (EPS) for the quarter. NIOX Group had a return on equity of 10.01% and a net margin of 14.74%. As a group, equities analysts anticipate that NIOX Group Plc will post 1.17 earnings per share for the current year.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.